BridgeBio Pharma (BBIO, $16.52) soars 52% and failed after exceeding expectations in a dwarfism study.
On March 01, 2023, BridgeBio Pharma (BBIO) experienced a significant shift in its stock performance as the 50-day moving average moved above the 200-day moving average. This is known as a "golden cross" in technical analysis and is often considered a bullish signal for the stock's future performance.
This news comes just days after BBIO's stock soared 52% following positive results from a clinical trial for treating dwarfism. The study, which exceeded expectations, showed promising results for the company's candidate drug to treat a specific form of dwarfism caused by a genetic mutation.
With the recent positive news from the dwarfism study, BBIO has seen a surge in investor interest and a boost in its stock price. The golden cross signal only adds to the optimism surrounding the company's future prospects.
BBIO's Stochastic Oscillator slumps oversold zone
The Stochastic Oscillator for BBIO moved into oversold territory on July 26, 2024. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Show more
Notable companies
The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Inovio Pharmaceuticals (NASDAQ:INO).
Industry description
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Market Cap
The average market capitalization across the Biotechnology Industry is 2.93B. The market cap for tickers in the group ranges from 151 to 570.15B. NONOF holds the highest valuation in this group at 570.15B. The lowest valued company is MYMX at 151.
High and low price notable news
The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 19%, and the average quarterly price growth was 20%. PIRS experienced the highest price growth at 127%, while NYMXF experienced the biggest fall at -94%.
Volume
The average weekly volume growth across all stocks in the Biotechnology Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was 54%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: -10 (-100 ... +100)